RU2018125290A - Фармацевтические композиции и их применение для лечения пигментного ретинита - Google Patents
Фармацевтические композиции и их применение для лечения пигментного ретинита Download PDFInfo
- Publication number
- RU2018125290A RU2018125290A RU2018125290A RU2018125290A RU2018125290A RU 2018125290 A RU2018125290 A RU 2018125290A RU 2018125290 A RU2018125290 A RU 2018125290A RU 2018125290 A RU2018125290 A RU 2018125290A RU 2018125290 A RU2018125290 A RU 2018125290A
- Authority
- RU
- Russia
- Prior art keywords
- arg
- aib
- ace
- phe
- pglu
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 6
- 208000007014 Retinitis pigmentosa Diseases 0.000 title claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 235000001014 amino acid Nutrition 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- PQBHGSGQZSOLIR-RYUDHWBXSA-N Arg-Phe Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PQBHGSGQZSOLIR-RYUDHWBXSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- QHSCIWIRXWFIGH-LURJTMIESA-N (2s)-2-amino-2-methylpentanedioic acid Chemical compound OC(=O)[C@](N)(C)CCC(O)=O QHSCIWIRXWFIGH-LURJTMIESA-N 0.000 claims 1
- GPYTYOMSQHBYTK-LURJTMIESA-N (2s)-2-azaniumyl-2,3-dimethylbutanoate Chemical compound CC(C)[C@](C)([NH3+])C([O-])=O GPYTYOMSQHBYTK-LURJTMIESA-N 0.000 claims 1
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 claims 1
- ARSWQPLPYROOBG-ZETCQYMHSA-N 2-methylleucine Chemical compound CC(C)C[C@](C)(N)C(O)=O ARSWQPLPYROOBG-ZETCQYMHSA-N 0.000 claims 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003889 eye drop Substances 0.000 claims 1
- 229940012356 eye drops Drugs 0.000 claims 1
- 239000003885 eye ointment Substances 0.000 claims 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 235000018977 lysine Nutrition 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 235000008729 phenylalanine Nutrition 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Claims (13)
1. Применение пептида общей формулы L1-X1-X2-X3-X4 или его солей, где:
L1 представляет собой Н, или ацил, или возможно N-ацилированную, и/или N-алкилированную, и/или Сα-алкилированную аминокислоту, выбранную из Glu, Gln, Pro, гидрокси-Pro, Azt, Pip, pGlu, Aib, Ас3с, Ac4c, Ac5c или Ас6с;
X1 и Х3, которые могут быть одинаковыми или разными, представляют собой возможно N-алкилированную и/или Сα-алкилированную основную аминокислоту, выбранную из Arg, Orn, и возможно гуанидилированного Lys, и фенилаланинов, замещенных в мета или пара положениях аминогруппой или группой гуанидино;
Х2 представляет собой возможно N-алкилированную аминокислоту, выбранную из Glu, Lys, α-метил-лейцина, α-метил-валина, α-метил-глутаминовой кислоты, Aib, Ас3с, Ас4с, Ас5с и Ас6с;
Х4 представляет собой гидрофобную аминокислоту, которая амидирована или не амидирована по С-концу и возможно Сα-алкилирована, выбранную из Phe, h-Phe, Tyr, Trp, 1-Nal, 2-Nal, h-1-Nal, h-2-Nal, Cha, Chg и Phg,
для лечения различных форм пигментного ретинита и его осложнений.
2. Применение по п. 1, где пептид выбран из Ace-Arg-Glu-Arg-Phe-NH2; pGlu-Arg-Glu-Arg-Tyr-OH; Glu-Arg-Glu-Arg-Phe-NH2; Ace-Arg-Glu-Arg-Tyr-NH2; Ace-Arg-Glu-Arg-Trp-NH2; Ace-Arg-Glu-N(Me)Arg-Phe-NH2; Ace-Arg-Glu-N(Me)Arg-Tyr-NH2; Ace-Arg-Glu-N(Me)Arg-Trp-NH2; pGlu-Arg-Glu-N(Me)Arg-Phe-NH2; pGlu-Arg-Glu-N(Me)Arg-Tyr-NH2; pGlu-Arg-Glu-N(Me)Arg-Trp-NH2; pGlu-Arg-Glu-Arg-Phe-NH2; pGlu-Arg-Glu-Arg-Tyr-NH2; pGlu-Arg-Glu-Arg-Trp-NH2; Ace-Arg-Aib-Arg-Phe-NH2; Ace-Arg-Aib-Arg-Tyr-NH2; Асе-Arg-Aib-Arg-Trp-NH2; Ace-Aib-Arg-Aib-Arg-Phe-NH2; Ace-Arg-Aib-N(Me)Arg-Phe-NH2; Ace-Arg-Aib-N(Me)Arg-Tyr-NH2; Ace-Arg-Aib-N(Me)Arg-Trp-NH2; pGlu-Arg-Aib-N(Me)Arg-Phe-NH2; Glu-Arg-Aib-N(Me)Arg-Tyr-NH2; pGlu-Arg-Aib-N(Me)Arg-Trp-NH2; pGlu-Arg-Aib-Arg-Phe-NH2; pGlu-Arg-Aib-Arg-Tyr-NH2; pGlu-Arg-Aib-Arg-Trp-NH2; Ace-Arg-Ac5c-Arg-Phe-NH2; Ace-Arg-Ac5c-Arg-Tyr-NH2; Ace-Arg-Ac5c-Arg-Trp-NH2; Ace-Arg-Ac5c-N(Me)Arg-Phe-NH2; Ace-Arg-Ac5c-N(Me)Arg-Tyr-NH2; Ace-Arg-Ac5c-N(Me)Arg-Trp-NH2; pGlu-Arg-Ac5c-N(Me)Arg-Phe-NH2; pGlu-Arg-Ac5c-N(Me)Arg-Tyr-NH2; pGlu-Arg-Ac5c-N(Me)Arg-Trp-NH2; pGlu-Arg-Ac5c-Arg-Phe-NH2; pGlu-Arg-Ac5c-Arg-Tyr-NH2; pGlu-Arg-Ac5c-Arg-Trp-NH2; Ace-Arg-Glu-Arg-Phe-OH; Ace-Arg-Glu-Arg-Tyr-OH; Ace-Arg-Glu-Arg-Trp-ОН; Ace-Arg-Glu-N(Me)Arg-Tyr-OH; pGlu-Arg-Glu-N(Me)Arg-Phe-OH; pGlu-Arg-Glu-Arg-Trp-OH; Ace-Arg-Aib-Arg-Phe-OH; Ace-Arg-Aib-N(Me)Arg-Phe-OH; pGlu-Arg-Aib-N(Me)Arg-Tyr-OH; pGlu-Arg-Aib-Arg-Trp-OH; Ace-Arg-Ac5c-Arg-Phe-OH; Ace-Arg-Ac5c-N(Me)Arg-Tyr-OH; pGlu-Arg-Ac5c-N(Me)Arg-Trp-OH; pGlu-Arg-Ac5c-Arg-Trp-ОН; Ace-N(Me)Arg-Aib-Arg-Phe-NH2; Ace-N(Me)Arg-Aib-N(Me)Arg-Phe-NH2; Ace-Arg-Aib-N(Me)Arg-Phe-NH2; Ace-Arg-Aib-Arg-α(Me)Phe-NH2; Ace-N(Me)Arg-Aib-Arg-α(Me)Phe-NH2; Ace-N(Me)Arg-Aib-N(Me)Arg-α(Me)Phe-NH2; Ace-Arg-Aib-N(Me)Arg-α(Me)Phe-NH2; Ace-Aib-N(Me)Arg-Aib-Arg-Phe-NH2; Ace-Aib-N(Me)Arg-Aib-N(Me)Arg-Phe-NH2; Ace-Aib-Arg-Aib-N(Me)Arg-Phe-NH2; Ace-Aib-Arg-Aib-Arg-α(Me)Phe-NH2; Ace-Aib-N(Me)Arg-Aib-Arg-α(Me)Phe-NH2; Ace-Aib-N(Me)Arg-Aib-N(Me)Arg-α(Me)Phe-NH2; Ace-Aib-Arg-Aib-N(Me)Arg-α(Me)Phe-NH2 или их солей.
3. Применение по п. 1, где пептид выбран из Ac-Arg-Aib-Arg-α(Me)Phe-NH2 или Ac-Aib-Arg-Aib-Arg-α(Me)Phe-NH2.
4. Фармацевтические композиции, содержащие один или более пептидов, как они определены в пп. 1-3, для применения в лечении различных форм пигментного ретинита и его осложнений.
5. Фармацевтические композиции по п. 4 для введения подкожным, внутримышечным, внутривенным, внутриглазным, пероральным, назальным, сублингвальным, местным, аэрозольным или трансдермальным путем, в виде глазных капель или глазных мазей, возможно содержащие дополнительные активные ингредиенты, носители и эксципиенты.
6. Фармацевтические композиции по п. 5 для подкожного введения.
7. Фармацевтические композиции по п. 5 для внутриглазного введения.
8. Фармацевтические композиции по пп. 4-7, где доза пептида находится в диапазоне от 10 мкг до 500 мг.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102016000001989 | 2016-01-12 | ||
| ITUB2016A009937A ITUB20169937A1 (it) | 2016-01-12 | 2016-01-12 | Formulazioni farmaceutiche e loro uso per il trattamento della retinite pigmentosa |
| PCT/EP2017/050497 WO2017121766A1 (en) | 2016-01-12 | 2017-01-11 | Pharmaceutical formulations and their use for the treatment of retinitis pigmentosa |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2018125290A true RU2018125290A (ru) | 2020-02-13 |
| RU2018125290A3 RU2018125290A3 (ru) | 2020-06-22 |
Family
ID=55806719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018125290A RU2018125290A (ru) | 2016-01-12 | 2017-01-11 | Фармацевтические композиции и их применение для лечения пигментного ретинита |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20180353565A1 (ru) |
| EP (1) | EP3402504A1 (ru) |
| JP (1) | JP2019504006A (ru) |
| KR (1) | KR20180100574A (ru) |
| CN (1) | CN108463237A (ru) |
| AU (1) | AU2017206626A1 (ru) |
| CA (1) | CA3011077A1 (ru) |
| HK (1) | HK1259382A1 (ru) |
| IL (1) | IL260517B (ru) |
| IT (1) | ITUB20169937A1 (ru) |
| RU (1) | RU2018125290A (ru) |
| WO (1) | WO2017121766A1 (ru) |
| ZA (1) | ZA201804589B (ru) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019245012A1 (ja) * | 2018-06-21 | 2019-12-26 | 第一三共株式会社 | 網膜色素変性症治療用ペプチド |
| IT202200007754A1 (it) | 2022-04-19 | 2023-10-19 | Iridea S R L | Nuovi composti con attivita’ farmacologica |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2236157A1 (en) | 1995-11-29 | 1997-06-05 | Amgen Inc. | Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (gdnf) protein product |
| DE69739190D1 (de) | 1996-10-28 | 2009-02-12 | Senju Pharma Co | Arzneimittel zur behandlung von oculären kreislauferkrankungen |
| FR2784898A1 (fr) | 1998-10-26 | 2000-04-28 | Univ Pasteur | Utilisation du gdnf pour le traitement de la degenerescence retinienne |
| WO2003007979A1 (en) | 2001-07-18 | 2003-01-30 | Board Of Regents, The University Of Texas System | An anti-angiogenic state in mice and humans with retinal photorecptor cell degeneration |
| JP4953040B2 (ja) | 2001-09-19 | 2012-06-13 | 株式会社フジモト・コーポレーション | アポトーシス抑制剤 |
| US20080317885A1 (en) | 2005-07-15 | 2008-12-25 | Baker Donald J | Compositions and Methods for Treating and Preventing Inflammatory and/or Degenerative Processes in Humans and Other Animals |
| PL1904056T3 (pl) | 2005-07-18 | 2009-09-30 | Minu Llc | Zastosowanie makrolidu do przywracania czucia rogówkowego |
| ITMI20061607A1 (it) * | 2006-08-09 | 2008-02-10 | Maria Vincenza Carriero | Peptidi con attivita farmacologica |
| JP2008247898A (ja) | 2007-03-08 | 2008-10-16 | Santen Pharmaceut Co Ltd | トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤 |
| WO2009089399A2 (en) | 2008-01-10 | 2009-07-16 | Bausch & Lomb Incorporated | Compositions comprising toll-like receptor or coreceptor antagonists and methods for ocular neuroprotection |
| WO2009111169A2 (en) | 2008-02-29 | 2009-09-11 | Bausch & Lomb Incorporated | Compositions comprising pkc-delta modulators and methods for ocular neuroprotection |
| US20120108654A1 (en) | 2008-06-30 | 2012-05-03 | The Johns Hopkins University | Compositions and methods for the treatment of ocular oxidative stress and retinitis pigmentosa |
| EP2251028A1 (en) | 2009-05-12 | 2010-11-17 | Biocompatibles Uk Ltd. | Treatment of eye diseases using encapsulated cells encoding and secreting an anti-angiogenic factor and/or a neuroprotective factor |
| JP2012062258A (ja) | 2010-09-14 | 2012-03-29 | Oriza Yuka Kk | 血管新生抑制剤及びそれを用いた眼疾患予防・治療剤 |
| KR102110200B1 (ko) | 2011-04-26 | 2020-05-13 | 레트로토프 인코포레이티드 | 산화성 망막 질환 |
| US20150328337A1 (en) | 2012-12-19 | 2015-11-19 | The Johns Hopkins University | Protection from oxidative damage by gene transfer by glutamate cysteine ligase and glutathione synthase |
| WO2014100433A1 (en) * | 2012-12-19 | 2014-06-26 | Brown University | Methods for treatment of microcephaly associated autism disorders |
| EP2898896A1 (en) | 2014-01-22 | 2015-07-29 | Université Pierre et Marie Curie (Paris 6) | Agents for use in the treatment of retinal inflammation |
| EP3331897B1 (en) * | 2015-08-05 | 2021-03-24 | Allergan, Inc. | Phenyl urea analogs as formyl peptide receptor 1 (fpr1) selective agonists |
-
2016
- 2016-01-12 IT ITUB2016A009937A patent/ITUB20169937A1/it unknown
-
2017
- 2017-01-11 RU RU2018125290A patent/RU2018125290A/ru not_active Application Discontinuation
- 2017-01-11 AU AU2017206626A patent/AU2017206626A1/en not_active Abandoned
- 2017-01-11 JP JP2018530866A patent/JP2019504006A/ja active Pending
- 2017-01-11 CA CA3011077A patent/CA3011077A1/en not_active Abandoned
- 2017-01-11 WO PCT/EP2017/050497 patent/WO2017121766A1/en not_active Ceased
- 2017-01-11 HK HK19101750.7A patent/HK1259382A1/zh unknown
- 2017-01-11 KR KR1020187019687A patent/KR20180100574A/ko not_active Withdrawn
- 2017-01-11 EP EP17702530.1A patent/EP3402504A1/en not_active Withdrawn
- 2017-01-11 US US16/069,102 patent/US20180353565A1/en not_active Abandoned
- 2017-01-11 CN CN201780006228.3A patent/CN108463237A/zh active Pending
-
2018
- 2018-07-10 ZA ZA2018/04589A patent/ZA201804589B/en unknown
- 2018-07-10 IL IL260517A patent/IL260517B/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017121766A1 (en) | 2017-07-20 |
| US20180353565A1 (en) | 2018-12-13 |
| IL260517B (en) | 2020-04-30 |
| CN108463237A (zh) | 2018-08-28 |
| EP3402504A1 (en) | 2018-11-21 |
| KR20180100574A (ko) | 2018-09-11 |
| AU2017206626A1 (en) | 2018-07-26 |
| HK1259382A1 (zh) | 2019-11-29 |
| ZA201804589B (en) | 2019-09-25 |
| JP2019504006A (ja) | 2019-02-14 |
| RU2018125290A3 (ru) | 2020-06-22 |
| CA3011077A1 (en) | 2017-07-20 |
| ITUB20169937A1 (it) | 2017-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551066A1 (en) | Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant | |
| PH12020551691A1 (en) | Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid | |
| JP2013533864A5 (ru) | ||
| IL262805B1 (en) | CD47 agonist factors for inducing programmed cell death and their use in the treatment of diseases associated with defects in programmed cell death | |
| JP2013155195A5 (ru) | ||
| ME02425B (me) | Peptidi koji imaju farmakološku aktivnost za liječenje poremećaja povezanih sa izmijenjenom migracijom ćelija, kao što je kancer | |
| JP2013511554A5 (ru) | ||
| AU2013221432A1 (en) | Peptidomimetic macrocycles | |
| CY1120618T1 (el) | Αναλογα αγωνιστων υποδοχεων mu οπιοειδων των ενδομορφινων | |
| CN106232616A (zh) | 两亲性合成抗菌肽、其药物组合物及其用途 | |
| JP2018504901A5 (ru) | ||
| EA201990885A1 (ru) | Композиции, содержащие короткие пептиды, полученные из pedf, и их применение | |
| RU2019126232A (ru) | Пептиды и способы для лечения диабета | |
| MY199821A (en) | Modified lipidated relaxin b chain peptides and their therapeutic use | |
| NZ708990A (en) | Method for activating helper t cell | |
| RU2015103816A (ru) | ПРОНИКАЮЩИЕ В КЛЕТКУ ПЕПТИДЫ, МИШЕНЬЮ КОТОРЫХ ЯВЛЯЕТСЯ eIF4E | |
| NZ756128A (en) | Novel peptides and analogs for use in the treatment of oral mucositis | |
| RU2018125290A (ru) | Фармацевтические композиции и их применение для лечения пигментного ретинита | |
| RU2010126154A (ru) | Эпитопные пептиды stat3 | |
| RU2011133224A (ru) | Новые фармацевтические композиции | |
| RU2018125296A (ru) | Фармацевтические композиции для лечения диабета | |
| US20200368338A1 (en) | Conjugate of wt1-derived peptides and composition comprising the same | |
| PT2717896T (pt) | Agentes terapêuticos para a regulação do fósforo sérico | |
| MX2018012716A (es) | Peptidos bioactivos pegilados y usos de los mismos. | |
| JP2015514771A5 (ru) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20201111 |